PlasmaTech Biopharmaceuticals Inc. (Nasdaq: PTBI) closed its
acquisition of Abeona Therapeutics. Also, H.C. Wainwright initiated
coverage of PlasmaTech Biopharmaceuticals with a Buy rating. The stock price soared $1.29 to close at $9.27.
PlasmaTech initiated with Buy
May 18, 2015 at 17:21 PM EDT
